Results 141 to 150 of about 12,660 (249)

Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development

CPT: Pharmacometrics & Systems Pharmacology
This review examines the application of machine learning (ML) in physiologically based pharmacokinetic (PBPK) modeling through improved prediction of input parameters, particularly via quantitative structure–activity relationship (QSAR) models, for ...
Xinyue Chen, Zhoumeng Lin
doaj   +1 more source

A permeability- and perfusion-based PBPK model for improved prediction of concentration-time profiles. [PDF]

Clin Transl Sci, 2022
Korzekwa K, Radice C, Nagar S.
europepmc   +1 more source

Intestinal Organoid‐Based Mathematical Modeling Predicts Clinical Gastrointestinal Toxicity of Oral Oncology Drugs

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Gastrointestinal (GI) toxicity is a common and potentially severe side effect of antiproliferative cancer therapies that often requires dose reduction or treatment interruption. Despite the clinical implications, there are currently no robust strategies for quantitative preclinical assessment of GI toxicity.
Carmen Pin, Deepa Maheshvare M., Louis Gall, Andrew Hall, Muireann Coen, Ambra Bianco, Shimeng Liu, Kenneth Pryde   +7 more
wiley   +1 more source

Correction to: A PBPK model to evaluate zebrafish eleutheroembryos' actual exposure: bisphenol A and analogs' (AF, F, and S) case studies. [PDF]

Environ Sci Pollut Res Int, 2023
Billat PA, Brochot C, Brion F, Beaudouin R.   +3 more
europepmc   +1 more source

From Models to Medicines: A Narrative History and Regulatory Perspective on the Translational Impact of Model‐Informed Drug Development (MIDD)

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Model‐informed drug development (MIDD) has grown from a constellation of methodological advances to a profound reorientation of how evidence is generated, evaluated, integrated, and leveraged in both drug development and regulatory decision‐making.
Issam Zineh
wiley   +1 more source

Global Sensitivity Analysis of a Physiologically-based Pharmacokinetic (PBPK) Model of Bromochloromethane [PDF]

, 2020
Sawyer, Colton
core   +1 more source

Health Risk Assessment in Children Occupationally and Para-Occupationally Exposed to Benzene Using a Reverse-Translation PBPK Model. [PDF]

Int J Environ Res Public Health, 2023
Pech K, Pérez-Herrera N, Vértiz-Hernández ÁA, Lajous M, Farías P.   +4 more
europepmc   +1 more source

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents. While the latter have shown success in the clinic, efficacy has been constrained by therapeutic resistance, limited tumor penetration, and suboptimal immune ...
Paulien Ravenstijn, Toru Kakinuma, Salaheldin Hamed, Takeshi Kadokura, Yohei Okada, Srinivasu Poondru   +5 more
wiley   +1 more source

A PBPK model to evaluate zebrafish eleutheroembryos' actual exposure: bisphenol A and analogs' (AF, F, and S) case studies. [PDF]

Environ Sci Pollut Res Int, 2023
Billat PA, Brochot C, Brion F, Beaudouin R.   +3 more
europepmc   +1 more source

Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Oligonucleotide therapies have emerged as a powerful therapeutic class, providing novel solutions for diverse diseases through antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers that specifically target and modulate gene expression or protein function. However, oligonucleotide development faces distinct challenges,
Ye Yuan, Vishnu Sharma, Venkatesh Atul Bhattaram, Xiaolei Pan, Justin Earp, Yun Wang, Jiang Liu, Hao Zhu   +7 more
wiley   +1 more source